Pneumology - Original Articles

Prognostic impact and factors associated with steroid-responsiveness in patients with hypersensitivity pneumonitis

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 24 February 2026
28
Views
19
Downloads

Authors

Hypersensitivity pneumonitis (HP) is an immune-mediated interstitial lung disease in which systemic corticosteroids remain first-line therapy despite limited evidence, especially in fibrotic forms. This study aimed to identify clinical, radiological, and biological features associated with functional response to steroids. We retrospectively analyzed 43 consecutive patients with HP treated with systemic corticosteroids and followed for at least 6 months. Patients were classified according to changes in forced vital capacity (FVC) as responders (≥5% increase), non-responders (≥5% decrease), or indifferent (±5%). Eighteen patients (42%) were responders, 15 (35%) indifferent, and 10 (23%) non-responders. Non-responders showed a consistently worse functional trajectory. A fibrosing high-resolution computed tomography pattern and baseline consolidations were more frequent in this group, as were precipitating antibodies against P. notatum and A. fumigatus. Conversely, bronchoalveolar lavage lymphocytosis >20% was more common among responders. Baseline FVC% and relative diffusing capacity of the lung for carbon monoxide were higher in non-responders, whereas demographic characteristics, smoking history, antigen exposure, comorbidities and autoantibody positivity did not differ significantly across groups. Fewer than half of patients experienced functional improvement after steroid therapy. Radiological fibrosis, consolidations, and specific precipitating antibodies were associated with lack of response, whereas bronchoalveolar lavage lymphocytosis predicted improvement. These findings highlight the heterogeneity of HP and may help identify patients unlikely to benefit from corticosteroids, supporting earlier consideration of alternative therapeutic strategies.

Downloads

Download data is not yet available.

Citations

Costabel U, Miyazaki Y, Pardo A, et al. Hypersensitivity pneumonitis. Nat Rev Dis Primer 2020;6:65.
Fernández Pérez ER, Travis WD, Lynch DA, et al. Diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 2021;160:e97-156.
Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020;202:e36-69.
Salisbury ML, Gu T, Murray S, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 2019;155:699-711.
Hamblin M, Prosch H, Vašáková M. Diagnosis, course and management of hypersensitivity pneumonitis. Eur Respir Rev 2022;31:210169.
Ejima M, Okamoto T, Suzuki T, et al. Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis. BMC Pulm Med 2021;21:243.
Tony FA, Soliman YMA, Salem HA. Effect of oral methyl prednisolone on different radiological patterns of hypersensitivity pneumonitis. J Asthma Allergy 2021;14:501-11.
De Sadeleer LJ, Hermans F, De Dycker E, et al. Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med 2018;8:14.
Lewandowska KB, Barańska I, Sobiecka M, et al. Factors predictive for immunomodulatory therapy response and survival in patients with hypersensitivity pneumonitis-retrospective cohort analysis. Diagn Basel Switz 2022;12:2767.
Elhennawy MG, Akl Y, Abbassi M, et al. The effectiveness and pharmacoeconomic study of using different corticosteroids in the treatment of hypersensitivity pneumonitis. BMC Pulm Med 2024;24:87.
Yoshizawa Y, Ohtani Y, Hayakawa H, et al. Chronic hypersensitivity pneumonitis in Japan: a nationwide epidemiologic survey. J Allergy Clin Immunol 1999;103:315-20.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70-88.
Holland AE, Spruit MA, Troosters T, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J 2014;44:1428-46.

Ethics Approval

The study protocol was approved by the Ethical Review Committee of ASST Brianza (Code 1538, 14 November 2019).

How to Cite



“Prognostic Impact and Factors Associated With Steroid-Responsiveness in Patients With Hypersensitivity Pneumonitis”. 2026. Monaldi Archives for Chest Disease, February. https://doi.org/10.4081/monaldi.2026.3865.